What is the newest approved oral antiviral treatment for chronic hepatitis B, including its dosing, indications, and monitoring?

The Newest Treatment for Chronic Hepatitis B

Tenofovir alafenamide (TAF) 25 mg daily is the newest approved oral antiviral for chronic hepatitis B, offering superior renal and bone safety compared to older agents while maintaining equivalent antiviral efficacy. TAF was approved in 2016 and represents a significant advancement over its predecessor tenofovir disoproxil fumarate (TDF) 1, 2.

Key Characteristics of TAF

TAF is a more stable prodrug that delivers tenofovir directly to hepatocytes with >90% lower systemic exposure compared to TDF, resulting in dramatically reduced renal and bone toxicity while maintaining potent HBV suppression 3, 4, 5.

Dosing and Administration

• Standard dose: 25 mg orally once daily 1
• Approved for patients ≥12 years of age 1
• Can be used in patients with creatinine clearance ≥15 mL/min 1
• Dose adjustment required if CrCl <15 mL/min 2

Efficacy Profile

TAF demonstrates non-inferior virological suppression compared to TDF:

For HBeAg-positive patients:

• 73% achieve HBV DNA <29 IU/mL at 48 weeks 1
• 18% HBeAg seroconversion rate 1
• 22% HBeAg loss 1

For HBeAg-negative patients:

• 90% achieve HBV DNA <29 IU/mL at 48 weeks 1
• 81% ALT normalization 1

Importantly, TAF shows superior ALT normalization rates compared to TDF when using AASLD criteria (male ≤30 U/L, female ≤19 U/L) 4, 5. This biochemical advantage persists through 96 weeks of treatment 2.

Safety Advantages Over TDF

Renal Protection

TAF causes significantly less decline in estimated glomerular filtration rate (eGFR) compared to TDF 2, 3, 4:

• Mean eGFR change at 144 weeks: +4.2 mL/min with TAF vs. -0.9 mL/min with TDF 2
• Patients switching from TDF to TAF show recovery of renal function to baseline levels 2
• Lower rates of proteinuria and proximal tubular dysfunction 1

Bone Mineral Density

TAF preserves bone density significantly better than TDF 2, 3:

• Hip BMD: median change +0.66% with TAF vs. -0.51% with TDF at 48 weeks 2
• Spine BMD: median change +1.74% with TAF vs. -0.11% with TDF 2
• Patients switching from TDF to TAF show recovery of BMD to baseline by week 240 2

Clinical Indications for TAF

TAF should be preferred over TDF in the following situations 2:

1. Treatment-naïve patients with or at risk of:

   • Renal dysfunction (eGFR <60 mL/min/1.73 m²)
   • Proteinuria (urine albumin/creatinine >30 mg/g)
   • Low serum phosphate (<2.5 mg/dL)
   • Metabolic bone disease

2. Patients currently on TDF who develop:

   • Declining renal function
   • Bone density loss
   • Risk factors for either condition

3. Elderly patients where renal and bone safety are paramount

Current Treatment Landscape

While TAF is the newest agent, the current first-line options for chronic hepatitis B include entecavir, TDF, and TAF 1, 2, 6. The 2018 AASLD guidelines and 2025 EASL guidelines recognize all three as acceptable first-line therapies 1, 6.

The choice between these agents should be based on:

• Patient age and comorbidities
• Baseline renal function
• Bone health status
• Prior treatment history
• Cost and availability

Emerging Evidence for Expanded Treatment

Groundbreaking data from the ATTENTION trial (2025) demonstrates that early TAF treatment in patients with moderate-to-high viremia but normal ALT significantly reduces serious liver-related events 7:

• Hazard ratio 0.21 (97.5% CI 0.04-1.20) for composite endpoint of HCC, decompensation, transplant, or death
• Incidence rate: 0.33 per 100 person-years with TAF vs. 1.57 with observation
• This challenges traditional treatment paradigms requiring elevated ALT 7

Monitoring Requirements

Patients on TAF require the following monitoring 1:

• Baseline: Creatinine clearance, serum phosphorus, urine glucose/protein, HIV testing
• During therapy:
  • Creatinine clearance, serum phosphorus, urine glucose/protein at least annually
  • More frequent monitoring if risk factors for renal impairment present
  • Lactic acid levels only if clinical concern arises

Common Pitfalls to Avoid

1. Do not use TAF in patients with CrCl <15 mL/min without dialysis - insufficient safety data 1
2. Do not assume TAF eliminates need for HCC surveillance - continue monitoring per guidelines 6
3. Test for HIV before initiating TAF - risk of HIV resistance if undiagnosed HIV infection 1
4. Do not discontinue TAF prematurely - long-term suppression required for optimal outcomes 6

Comparison with Other Current Agents

TAF vs. Entecavir: Both show excellent antiviral efficacy with high barriers to resistance. TAF offers better bone and renal safety profile than TDF, while entecavir remains an excellent alternative, particularly in treatment-naïve patients without renal/bone concerns 2, 8.

TAF vs. TDF: Equivalent antiviral efficacy but TAF demonstrates superior renal and bone safety, making it the preferred tenofovir formulation for most patients 2, 3, 4.

TAF vs. Besifovir: Besifovir (approved in South Korea) shows similar renal/bone safety advantages over TDF, but TAF has more extensive global clinical experience 2.